$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Latest from other desks

tml.the modern leap
Health / Medical Research

Vittoria CAR-T Posts 88 Percent Response in Lymphoma

Vittoria Biotherapeutics announced on Tuesday, November 17, 2026 that its Phase 1 VIPER-101 study of Senza5 CART5 in relapsed or refractory T-cell lymphoma recorded an 88 percent overall response rate and a 75 percent complete response rate in the study abstract. The Food and Drug Administration has granted the therapy Regenerative Medicine Advanced Therapy and Orphan Drug designations. The data are early Phase 1 results, and the company hasn't published a patient count in its announcement.

TML Health DeskNov 17, 12:14 PM ET · 2 min read

Edited and fact-checked by Stephen Sprague

An illustration of a T cell (archive). Senza5 CART5 engineers a patient's own T cells to attack T-cell lymphoma, a cancer of those same cells. Illustration: NIAID, via Wikimedia Commons.
Summary

Senza5 CART5 now heads toward a planned pivotal study, the larger trial that would decide whether the response rates survive a bigger and sicker patient group. The full dataset gets its public airing at the American Society of Hematology meeting in December.

Tap a passage. React to the part that matters.

A patient with relapsed T-cell lymphoma has usually already burned through the standard drug list. Vittoria Biotherapeutics built its therapy for that waiting room, and on Tuesday the company put its first human numbers on the record.

The Phase 1 VIPER-101 study tested Senza5 CART5, a CAR T-cell therapy made from a patient's own T cells. The study abstract reports an 88 percent overall response rate and a 75 percent complete response rate. The company also reports durable CD5-negative T-cell reconstitution, which means the engineered cells persisted and the patient's T-cell population rebuilt without the CD5 marker the therapy edits out.

T-cell lymphoma is a hard target for CAR T therapy for a structural reason. The cancer lives in the same cell type the therapy is made from, so engineered cells can attack each other or carry malignant cells into the product. Vittoria's Senza5 platform edits CD5 in the manufactured cells and uses a five day manufacturing process drawn from technology licensed from the University of Pennsylvania.

The Food and Drug Administration has granted Senza5 CART5 both Regenerative Medicine Advanced Therapy designation and Orphan Drug designation, and the company says the VIPER-101 dataset supported the RMAT decision. Neither designation is an approval. Each one speeds up the conversation with the agency, and the company plans to advance the program into a pivotal study.

The announcement doesn't state how many patients the response rates rest on, and that omission matters. In a small Phase 1 cohort, a handful of patients can swing a percentage by double digits. The oral presentation at the American Society of Hematology meeting, set for December 14, 2026 in New Orleans with Penn Medicine's Stefan K. Barta presenting, is where the cohort size and the adverse event record get their full hearing. The abstract notes delayed immune-mediated toxicity that the researchers describe as mechanistically tractable.

A second presentation covers LampTAC, the company's preclinical protein degradation platform, in a poster session the same day. LampTAC is laboratory work, not patient data, and it shouldn't be read with the same weight as the VIPER-101 results.

The Senza5 platform behind the therapy is built around manufacturing time. Vittoria says its process takes five days and is designed to preserve stemness in the engineered cells, a quality the company links to durability and potency after infusion. A shorter factory run matters to a relapsed patient in practical terms: less time between the cell collection and the infusion is less time for an aggressive lymphoma to move.

For patients with relapsed or refractory T-cell lymphoma, the next evidence that counts is the pivotal study: a larger cohort, a defined dose, and response durations measured in years rather than conference abstracts.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.